Gilead Sciences Inc (GILD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $207.86B
Last updated: Nov 17, 2026 at 4:44 PM ET
Gilead Sciences Inc (GILD) Statistics
Gilead Sciences (GILD) has a market cap of $207.86B and an enterprise value of $227.65B. It kept -12.47% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 9.52% above the market cap, as debt exceeds cash.
| Market Cap | $207.86B |
|---|---|
| Enterprise Value | $227.65B |
| Latest price (Nov 17, 2026) | $170.26 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 15, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Next Ex-Dividend Date | Dec 15, 2026 |
| Next Payment Date | Dec 30, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.8x and 16.2x. Its year-end P/S ranged from 3.0x to 5.2x from 2016 to 2025.
| P/S Ratio | 6.8x |
|---|---|
| Forward P/S | 6.6x |
| P/B Ratio | 16.2x |
| P/FCF Ratio | 15.3x |
| P/OCF Ratio | 14.4x |
Enterprise Valuation
Counting debt and cash, the company is valued at 178.9x EBITDA and 16.8x free cash flow.
| EV / Sales | 7.3x |
|---|---|
| EV / EBITDA | 178.9x |
| EV / FCF | 16.8x |
Price Statistics
The stock is up 37.86% over 52 weeks and trades 9.25% above its 50-day average.
| Beta (1Y) | 0.38 |
|---|---|
| 52-Week Change | +37.86% |
| 1-Month Change | +11.23% |
| 3-Month Change | +16.00% |
| 6-Month Change | +32.06% |
| 5-Year Change | +163.07% |
| 10-Year Change | +131.81% |
| Total Return (1Y) | +40.49% |
| Total Return (3Y CAGR) | +34.25% |
| Total Return (5Y CAGR) | +23.98% |
| Return vs SPY (1Y) | +23.96% |
| Max Drawdown (1Y) | -22.02% |
| Max Drawdown (3Y) | -26.58% |
| Sharpe Ratio (1Y) | 1.13 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $155.84 |
| 200-Day Average | $141.10 |
| 52-Week Range | $114.81 to $176.58 |
| RSI (14 Days) | 61.9 |
| Average Volume (20 Days) | 6.47M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.38x current liabilities, and total debt is 2.01x shareholder equity.
| Current Ratio | 1.38x |
|---|---|
| Quick Ratio | 1.22x |
| Debt / Equity | 2.01x |
| Debt / EBITDA | 20.29x |
| Debt / FCF | 1.90x |
| Interest Coverage | 10.57x |
Returns and Efficiency
Return on invested capital is -3.87% over the last 12 months, against a 5-year average of 12.31%.
| Return on Equity (ROE) | -29.62% |
|---|---|
| Return on Assets (ROA) | -7.51% |
| Return on Invested Capital (ROIC) | -3.87% |
| Return on Capital Employed (ROCE) | -3.86% |
| ROE (5Y Average) | 23.10% |
| ROA (5Y Average) | 8.12% |
| ROIC (5Y Average) | 12.31% |
| Asset Turnover | 0.56x |
| Inventory Turnover | 3.23x |
| Receivables Turnover | 6.16x |
| Cash Conversion Cycle | 125 days |
Scores
GILD has an Altman Z-Score of 4.00, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.00 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $30.99B over the last 12 months is up 6.54% from the 12 months before.
| Revenue | $30.99B |
|---|---|
| Revenue Growth (YoY) | +6.54% |
| Gross Profit | $24.77B |
| Operating Income | -$2.36B |
| Pretax Income | -$2.53B |
| Net Income | -$3.86B |
| EBITDA | $1.29B |
| EBIT | -$1.52B |
| Reported EPS (TTM) | -$0.31 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 25.36% of the $51.41B in total assets.
| Cash and Equivalents | $6.44B |
|---|---|
| Total Debt | $26.23B |
| Net Debt | $19.79B |
| Net Debt Per Share | $15.94 |
| Working Capital | $4.55B |
| Shareholder Equity | $13.04B |
| Book Value Per Share | $10.50 |
| Tangible Book Value | -$8.70B |
| Total Assets | $51.41B |
| Total Liabilities | $38.45B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $699.00M of capital spending, operating cash flow left $13.78B of free cash flow.
| Operating Cash Flow | $14.48B |
|---|---|
| Capital Expenditures | $699.00M |
| Free Cash Flow | $13.78B |
| FCF Per Share | $11.10 |
| Depreciation and Amortization | $2.81B |
| Dividends Paid | $4.10B |
| Share Repurchases | $1.37B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -7.62%, against a 5-year average of 26.21%.
| Gross Margin | 79.93% |
|---|---|
| Operating Margin | -7.62% |
| Pretax Margin | -8.18% |
| Net Margin | -12.47% |
| EBITDA Margin | 4.17% |
| EBIT Margin | -4.91% |
| FCF Margin | 44.47% |
| Gross Margin (5Y Average) | 77.64% |
| Operating Margin (5Y Average) | 26.21% |
| Net Margin (5Y Average) | 18.14% |
Growth
Revenue grew 2.57% a year over 3 years, and EPS 3.88% a year.
| Revenue Growth (3Y CAGR) | +2.57% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.58% |
| EPS Growth (3Y CAGR) | +3.88% |
| EPS Growth (5Y CAGR) | +2.83% |
| FCF Growth (3Y CAGR) | +4.26% |
| FCF Growth (5Y CAGR) | +4.69% |
| Operating Income Growth (3Y CAGR) | +10.99% |
| Book Value Per Share Growth (2Y CAGR) | -0.17% |
Dividends and Yields
GILD pays out 27.88% of earnings as dividends.
| Dividend Per Share (Annual) | $3.28 |
|---|---|
| Dividend Yield | 1.93% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +2.67% |
| Dividend Growth (5Y CAGR) | +3.04% |
| Payout Ratio | 27.88% |
| FCF Payout Ratio | 29.77% |
| FCF Yield | 6.52% |
| Buyback Yield | 0.51% |
| Shareholder Yield | 2.45% |
Stock Splits
The last split was a 2-for-1 forward split on Jan 28, 2013.
| Last Split Date | Jan 28, 2013 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 12 similar companies, GILD has the 3rd highest P/S and the 10th highest dividend yield.
P/S RatioPeer median 4.1x
ROICPeer median 13.95%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.31%
Dividend YieldPeer median 2.69%
| P/S Ratio | 6.8x vs 4.1x median |
|---|---|
| ROIC | -3.87% vs 13.95% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +6.54% vs +5.31% median |
| Dividend Yield | 1.93% vs 2.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.79% and EPS growth at 11.48% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.79% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +11.48% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GILD
What is GILD's market cap?
Gilead Sciences has a market cap of $207.86B. Its enterprise value, which adds debt and subtracts cash, is $227.65B.
How many shares of GILD are outstanding?
Gilead Sciences has 1.24B shares outstanding. The count is down 0.08% from a year earlier.
Does GILD pay a dividend?
Yes. Gilead Sciences pays $3.28 a share a year, a dividend yield of 1.93%.
How much debt does GILD have?
Gilead Sciences has $26.23B of total debt and $6.44B of cash and equivalents, a net debt position of $19.79B.
GILD pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts